Clinical Outcomes of Noninhibitor Patients with Hemophilia a Switching from Prophylaxis with Factor VIII to Emicizumab: A Meta-Analysis of Real-World Evidence Studies

被引：0
|
作者：
Escobar, Miguel A. [1 ]
Fan, Qi Angela [2 ]
Mokdad, Ali G. [3 ]
Tarantino, Michael D. [4 ]
Burgess, Benjamin [5 ]
Hawe, Emma [5 ]
Fernandez, Maria [6 ]
Bullano, Michael [2 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, Div Hematol & Oncol, Dept Med, Houston, TX USA
[2] Takeda Pharmaceut Inc, Lexington, MA USA
[3] Takeda Pharmaceut, Cambridge, MA USA
[4] Univ Illinois, Coll Med, Bleeding & Clotting Disorders Inst, Peoria, IL USA
[5] RTI Hlth Solut, Manchester, Lancs, England
[6] RTI Hlth Solut, Res Triangle Pk, NC USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors
    Escobar, Miguel
    Bullano, Michael
    Mokdad, Ali G.
    Caicedo, Jorge
    Schultz, Bob G.
    Fan, Qi
    Verma, Sumit
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (06) : 467 - 474
  • [2] IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Robert G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E34 - E34
  • [3] Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Bob G. G.
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 574 - 580
  • [4] Laboratory and Bleeding Frequency Changes in Pediatric Patients after Transitioning from Factor VIII to Emicizumab Prophylaxis -Real World Evidence in Patients with Severe Hemophilia a
    Jain, Akshat
    Sheth, Parthiv V.
    BLOOD, 2023, 142
  • [5] Real-World Clinical and Laboratory Characteristics in Severe Hemophilia a Patients Commencing Emicizumab
    Ling, Gavin
    Ajidahun, Aderonke
    Austin, Steve K.
    Dolan, Gerard
    McCormick, Aine
    BLOOD, 2020, 136
  • [6] Real-World Persistence with and Adherence to Emicizumab Prophylaxis in Persons with Hemophilia a: A Secondary Claims Database Analysis
    Mahajerin, Arash
    Khairnar, Rahul
    Meyer, Craig S.
    Abbass, Ibrahim M.
    Wang, Rongrong
    Lee, Lucy
    Tzeng, Eunice
    Raimundo, Karina
    BLOOD, 2020, 136
  • [7] Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
    Liu, Guoqing
    Huang, Kun
    Li, Gang
    Zhen, Yingzi
    Li, Zhengping
    Chen, Zhenping
    Wu, Runhui
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [8] INVASIVE PROCEDURES IN PATIENTS WITH HAEMOPHILIA ON EMICIZUMAB PROPHYLAXIS: REAL-WORLD CLINICAL EXPERIENCE IN SLOVENIA
    Rener, K.
    Pompe, B.
    Doma, S. Anzej
    Kotnik, B. Faganel
    Kitanovski, L.
    Zupan, I. Preloznik
    HAEMOPHILIA, 2022, 28 : 66 - 66
  • [9] Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry
    Poon, Man-Chiu
    Lee, Adrienne
    Germini, Federico
    Keepanasseril, Arun
    Ibrahim, Quazi
    Nissen, Francis
    Moreno, Katya
    Santos, Michelle
    Iserman, Emma
    Matino, Davide
    Iorio, Alfonso
    BLOOD, 2022, 140 : 8465 - 8467
  • [10] Emicizumab in Management of Hemophilia_A Patients with High Titer FVIII Inhibitor - Real-World Evidence from Poland
    Windyga, Jerzy
    Zdziarska, Joanna
    Stefanska-Windyga, Ewa
    Chmielewska, Ewa
    Chojnowski, Krzysztof
    Jamrozik, Michal
    Kostyra, Aleksandra
    Kozinska, Justyna
    Krainiak, Halyna
    Oleksiuk, Jolanta
    Rupa-Matysek, Joanna
    Zarzycka, Ewa
    Buczma, Anna
    BLOOD, 2022, 140 : 5621 - 5622
12345